Skip to content

Study · Randomized controlled trial · n = 46 · 2006

3 results

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.

Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L

Cancer1 Nov 2006Cited by 54 (Europe PMC)

PMID17054107 (opens in a new tab)DOI10.1002/cncr.22272 (opens in a new tab)PepBankPUB-17054107
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In neuroendocrine tumor patients, lanreotide Autogel was noninferior to microparticles for tumor marker response (55% versus 59%).

    In plain wordsIn neuroendocrine tumor patients, lanreotide Autogel was noninferior to lanreotide microparticles for tumor marker response.

    Peptide
    Lanreotide
    Outcome
    Not applicableTumor marker response
    Study

    n = 46

    Comparator
    lanreotide microparticles 60 mg intramuscular every 3 weeks
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 6 weeks · deep subcutaneous · 3 injections, 6 weeks apart (assessed between baseline and Week 18)As given in this study (human).

    Measurements

    patients responding on tumor markers
    55%
    lanreotide Autogel 120 mg
    patients responding on tumor markers
    59%
    lanreotide microparticles 60 mg

    Source sentences

    Summary
    Both for tumor markers and for tumor size, Lan ATG was not inferior to Lan MP (55% and 59% of patients responded on tumor markers, respectively; 68% and 66% of patients responded on tumor size, respectively).
    3 context sentences
    Summary · context
    Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial.
    Summary · context
    Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks).
    Summary · context
    Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In neuroendocrine tumor patients, lanreotide Autogel was noninferior to microparticles for tumor size response (68% versus 66%).

    In plain wordsIn neuroendocrine tumor patients, lanreotide Autogel was noninferior to lanreotide microparticles for tumor size response.

    Peptide
    Lanreotide
    Outcome
    Not applicableTumor size response
    Study

    n = 46

    Comparator
    lanreotide microparticles 60 mg intramuscular every 3 weeks
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 6 weeks · deep subcutaneous · 3 injections, 6 weeks apart (assessed between baseline and Week 18)As given in this study (human).

    Measurements

    patients responding on tumor size
    68%
    lanreotide Autogel 120 mg
    patients responding on tumor size
    66%
    lanreotide microparticles 60 mg

    Source sentences

    Summary
    Both for tumor markers and for tumor size, Lan ATG was not inferior to Lan MP (55% and 59% of patients responded on tumor markers, respectively; 68% and 66% of patients responded on tumor size, respectively).
    3 context sentences
    Summary · context
    Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial.
    Summary · context
    Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks).
    Summary · context
    Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18.
  3. 03HumanRandomized controlled trialSafety outcome

    In neuroendocrine tumor patients, lanreotide Autogel and microparticles were well tolerated, with no safety concerns identified.

    In plain wordsIn neuroendocrine tumor patients, both lanreotide formulations were well tolerated, with no safety concerns identified.

    Peptide
    Lanreotide
    Outcome
    Not applicableTolerability
    Study

    n = 46

    Comparator
    lanreotide microparticles 60 mg intramuscular every 3 weeks
    Outcome group
    Adverse events · Whole body
    Studied dose
    120 mg every 6 weeks · deep subcutaneous · 3 injections, 6 weeks apart (assessed between baseline and Week 18)As given in this study (human).

    Source sentences

    Summary
    Both treatments were tolerated well, and no safety concerns were identified.
    3 context sentences
    Summary · context
    Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial.
    Summary · context
    Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks).
    Summary · context
    Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.